Michael A Davies

Michael A Davies

UNVERIFIED PROFILE

Are you Michael A Davies?   Register this Author

Register author
Michael A Davies

Michael A Davies

Publications by authors named "Michael A Davies"

Are you Michael A Davies?   Register this Author

100Publications

4211Reads

39Profile Views

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

N Engl J Med 2019 08 4;381(7):626-636. Epub 2019 Jun 4.

From Institut Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Aix-Marseille University, Marseille (J.J.G.), and Assistance Publique-Hôpitaux de Paris Dermatology and Clinical Investigation Center, Unité 976, Université de Paris, Hôpital Saint-Louis, Paris (C.L.) - all in France; Moscow City Oncology Hospital, Moscow (D. Stroyakovskiy), and the Petrov Research Institute of Oncology, St. Petersburg (E.L.) - both in Russia; Przychodnia Lekarska Komed, Konin (B.K.), the University of Medical Sciences, Poznań (A.M.), and the Maria Skłodowska-Curie Institute-Oncology Center, Warsaw (P.R.) - all in Poland; the University Hospital Schleswig-Holstein, Kiel (A.H.), the Department of Dermatology, University of Tübingen, Tübingen (C.G.), University Hospital Essen, Essen (D. Schadendorf), and the German Cancer Consortium, Heidelberg (D. Schadendorf) - all in Germany; the Veneto Institute of Oncology, Padua (V.C.S.), and Papa Giovanni XXIII Hospital, Bergamo (M.M.) - both in Italy; the Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer (J.S.), and Sackler Medical School, Tel Aviv University, Tel Aviv (J.S.) - both in Israel; Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine (I.B.); Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens (H.G.); the Netherlands Cancer Institute, Amsterdam (J.B.A.G.H.); Mount Vernon Cancer Centre, Northwood, United Kingdom (P.D.N.); the University of California, Los Angeles, Los Angeles (A.R.); the University of Texas M.D. Anderson Cancer Center, Houston (M.A.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (K.T.F.); Novartis Pharma, Basel, Switzerland (P.B.); Novartis Pharmaceuticals, East Hanover, NJ (M.T., E.G., M.V.); and the Melanoma Institute Australia, the University of Sydney, and Royal North Shore and Mater Hospitals, Sydney (G.V.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1904059DOI Listing
August 2019

Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).

J Neurooncol 2019 May 7;142(3):499-509. Epub 2019 Mar 7.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-019-03121-2DOI Listing
May 2019

Reply to A. Shinde et al.

J Clin Oncol 2019 Apr 26;37(12):1031-1032. Epub 2019 Feb 26.

Harriet M. Kluger, MD, Yale School of Medicine, New Haven, CT; Kim A. Margolin, MD, City of Hope, Duarte, CA; Michael A. Davies, MD, PhD, MD Anderson Cancer Center, Houston, TX; Georgina V. Long, PhD, The University of Sydney, Sydney, NSW, Australia; Hussein A. Tawbi, MD, PhD, MD Anderson Cancer Center, Houston, TX; and Sarah B. Goldberg, MD and Veronica L. Chiang, MD, Yale School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.02463
Publisher Site
http://dx.doi.org/10.1200/JCO.18.02463DOI Listing
April 2019

Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:e59-e69. Epub 2019 May 17.

4 Department of Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_241345DOI Listing
January 2019

ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.

Mol Cancer Res 2018 11 12;16(11):1724-1736. Epub 2018 Jul 12.

Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-18-0171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214753PMC
November 2018

Estrogen returns to the stage in melanoma.

Pigment Cell Melanoma Res 2018 09 29;31(5):554-555. Epub 2018 Apr 29.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12706DOI Listing
September 2018

Role of Elevated Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma.

Clin Cancer Res 2018 09 18;24(17):4119-4125. Epub 2018 May 18.

Center for Melanoma Research and Treatment, California Pacific Medical Center (CPMC) Research Institute, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-0791DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125189PMC
September 2018

Sex as a predictor of response to cancer immunotherapy.

Lancet Oncol 2018 08;19(8):e376

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30483-2DOI Listing
August 2018

Body-mass index and metastatic melanoma outcomes - Authors' reply.

Lancet Oncol 2018 05;19(5):e227-e228

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30266-3DOI Listing
May 2018

Melanoma brain metastases harboring BRAF or NRAS mutations are associated with an increased local failure rate following conventional therapy.

J Neurooncol 2018 Mar 2;137(1):67-75. Epub 2017 Dec 2.

Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 97, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-017-2695-2DOI Listing
March 2018

Melanoma in 2017: Moving treatments earlier to move further forwards.

Nat Rev Clin Oncol 2018 02 28;15(2):75-76. Epub 2017 Nov 28.

Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.183DOI Listing
February 2018

Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications.

Pigment Cell Melanoma Res 2018 01 2;31(1):11-30. Epub 2017 Nov 2.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12661DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742019PMC
January 2018

Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.

Melanoma Res 2017 12;27(6):545-557

aThe Hormel Institute, University of Minnesota, Austin, Minnesota bDepartment of Medicine and Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania Departments of cOncological Sciences dSurgery eDermatology fHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah gDepartment of Tumor Biology, Tumor Biology hDepartment of Cutaneous Oncology, Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida iDepartment of Medicine, Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital jDepartment of Global Health, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, DC kDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000403DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683096PMC
December 2017

Primary medical therapy for BRAF-mutant melanoma brain metastases-is this good enough? - Authors' reply.

Lancet Oncol 2017 09;18(9):e509

Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30640-XDOI Listing
September 2017

Melanoma Brain Metastases: Current Areas of Investigation and Future Directions.

Cancer J 2017 Jan/Feb;23(1):68-74

From the Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000237DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300745PMC
August 2017

Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma.

Clin Cancer Res 2017 Aug 7;23(16):4831-4842. Epub 2017 Apr 7.

Division of Molecular Oncology, Department of Translational Molecular Medicine, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0146DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559338PMC
August 2017

Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes.

J Invest Dermatol 2017 08 23;137(8):1792-1795. Epub 2017 Apr 23.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2017.04.007DOI Listing
August 2017

Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.

Mol Cancer Ther 2017 03 30;16(3):516-528. Epub 2017 Jan 30.

Department of Cancer Biology and Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-16-0552DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337170PMC
March 2017

Assessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors.

JAMA Dermatol 2017 Feb;153(2):228-229

Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2016.4068DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484732PMC
February 2017

Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.

Cancer Cell 2017 02;31(2):225-239

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.01.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501076PMC
February 2017

An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.

Cancer Res 2016 09 3;76(18):5455-66. Epub 2016 Aug 3.

Department of Cancer Biology and Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. Department of Cutaneous Biology and Dermatology, Thomas Jefferson University, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-3384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026598PMC
September 2016

RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma.

Oncotarget 2016 Jun;7(24):36711-36718

Department of Cell and Molecular Biology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.9164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095033PMC
June 2016

How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?

J Natl Compr Canc Netw 2016 06;14(6):787-92

Departments of Pathology, The University of Texas MD Anderson Cancer Center, Houston Texas

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0079DOI Listing
June 2016

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma.

Arch Pathol Lab Med 2016 Apr 4;140(4):355-7. Epub 2015 Sep 4.

From the Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (Dr Sholl);

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2015-0278-CPDOI Listing
April 2016

MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.

J Invest Dermatol 2016 Feb 20;136(2):453-463. Epub 2015 Nov 20.

Department of Cancer Biology and Sidney Kimmel Cancer Center, Thomas Jefferson University Philadelphia, Pennsylvania, USA; Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2015.11.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789776PMC
February 2016

Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression.

Sci Rep 2016 Jan 20;6:19649. Epub 2016 Jan 20.

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep19649DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726397PMC
January 2016

Role of Increased n-acetylaspartate Levels in Cancer.

J Natl Cancer Inst 2016 Jan 26;108(6):djv426. Epub 2016 Jan 26.

Departments of Gynecologic Oncology and Reproductive Medicine (BZ, RAP, RR, TM, ASN, HJD, WH, CI, SYW, KMG, SP, LSM, AMN, GAP, AKS), Cancer Systems Imaging (NMZ, CRM, PKB), Biostatistics (MG), Cancer Medicine (CVP), Center for RNA Interference and Non-Coding RNA (CI, LSM, CRA, GLB, AKS), Cancer Biology (YS, MBE, GLB, AKS), Experimental Therapeutics (CRA, GLB), Bioinformatics and Computational Biology (YW, KAB), Melanoma Medical Oncology (MAD), and Pathology (JL), University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Nanomedicine and Bioengineering, UT Health, Houston, TX (GLB, AKS); Departments of Psychology, Urology, and Obstetrics and Gynecology, the University of Iowa, Iowa City, IA (SKL); Laboratory for Systems Biology of Human Diseases (LY, JB, AA, DN), Department of Chemical and Biomolecular Engineering (LY, JB, AA, DN), and Department of Bioengineering (DN), Rice University, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv426DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849357PMC
January 2016

Molecular approaches to tumor inhibition in melanoma.

Authors:
Michael A Davies

Clin Adv Hematol Oncol 2015 Dec;13(12):831-3

The University of Texas, MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
December 2015

AKT1 Activation Promotes Development of Melanoma Metastases.

Cell Rep 2015 Nov 22;13(5):898-905. Epub 2015 Oct 22.

Department of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA. Electronic address:

View Article

Download full-text PDF

Source
http://www.cell.com/cell-reports/pdf/S2211-1247(15)01082-7.p
Web Search
http://www.cell.com/cms/attachment/2040452974/2053964384/mmc
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S221112471501082
Publisher Site
http://dx.doi.org/10.1016/j.celrep.2015.09.057DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646731PMC
November 2015

Converting biology into clinical benefit: lessons learned from BRAF inhibitors.

Melanoma Manag 2015;2(3):241-254

The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.15.18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649930PMC
January 2015